Patients taking a BRAF inhibitor are more susceptible to highly volatile melanocytic lesions that make the detection of new primary melanomas more difficult, according to results shared in a research letter published in JAMA: Dermatology.
MRV Research
Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity
The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO 2014) in Chicago in June.
Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma
Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research showing promise for pembrolizumab in advanced melanoma.
More than 40 melanoma-specific genes determine disease aggressiveness
Researchers have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis.